Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a study of BIVV020 in adults with persistent/chronic immune thrombocytopenia
2020-004162-18Phase 2Completed
- Sponsor
- Sanofi
- Start
- Feb 2021
- Modality
- IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of riliprubart in immune thrombocytopenia (ITP), sponsored by Sanofi. Primary endpoint: Durable platelet response. Started Feb 2021; status: completed.
02
Drugs
riliprubart
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on 2020-004162-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004162-18.